Default: Drugs in R and D

ISSN: 1174-5886

Journal Home

Journal Guideline

Drugs in R and D Q2 Unclaimed

Adis International Ltd United Kingdom
Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Drugs in R and D is a journal indexed in SJR in Pharmacology with an H index of 56. It is an CC BY-NC Journal with a Single blind Peer Review review system, and It has a price of 2700 €. The scope of the journal is focused on pharmacology, drug development, drug research. It has an SJR impact factor of 0,691 and it has a best quartile of Q2. It is published in English. It has an SJR impact factor of 0,691.

Type: Journal

Type of Copyright: CC BY-NC

Languages: English

Open Access Policy: Open Access

Type of publications:

Publication frecuency: -

DOAJ Scopus WOS
Categories: Pharmacology (Q2)
Price

2700 €

Inmediate OA

NPD

Embargoed OA

- €

Non OA

Metrics

Drugs in R and D

0,691

SJR Impact factor

56

H Index

50

Total Docs (Last Year)

111

Total Docs (3 years)

1772

Total Refs

264

Total Cites (3 years)

108

Citable Docs (3 years)

2.23

Cites/Doc (2 years)

35.44

Ref/Doc

Comments

No comments ... Be the first to comment!

Aims and Scope


Pharmacology Drug development Drug research



Best articles by citations

Alvimopan

View more

Enrasentan

View more

Safety and Efficacy of 0.5% Carbomer 980 Gel for Treatment of Symptoms of Common Cold: Results of 2 Randomized Trials

View more

Itasetron

View more

Pharmacology and Metabolism of Renzapride

View more

Risedronic Acid

View more

Has Molecular and Cellular Imaging Enhanced Drug Discovery and Drug Development?

View more

Agents in Development for the Treatment of Hepatitis C

View more

Effects of Concurrent Therapy with Policosanol and Omega-3 Fatty Acids on Lipid Profile and Platelet Aggregation in Rabbits

View more

CJ 11974

View more

Effect of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Omeprazole Plasma Pharmacokinetics in Healthy Adults

View more

A Chaperone-Mediated Approach to??Enzyme Enhancement as a Therapeutic Option for the Lysosomal??Storage Disorders

View more
SHOW MORE ARTICLES

Teneligliptin, a Dipeptidyl Peptidase-4 Inhibitor, Improves Early-Phase Insulin Secretion in Drug-Na?Øve Patients with Type 2 Diabetes

View more

Effect of D-004, a Lipid Extract from the Cuban Royal Palm Fruit, on Atypical Prostate Hyperplasia Induced by Phenylephrine in Rats

View more

PEG interferon-a-2a

View more

Pharmacokinetic-Pharmacodynamic Interaction between Nebicapone, a Novel Catechol-O-Methyltransferase Inhibitor, and Controlled-Release Levodopa/Carbidopa 200 mg/50 mg

View more

Novel Genetic Techniques and Approaches in the Microbial Genomics Era

View more

Zatosetron

View more

Dosage Form Proportionality and Food Effect of the Final Tablet Formulation of Eslicarbazepine Acetate

View more

Six-Month Toxicity Study of Oral Administration of D-003 in Sprague Dawley Rats

View more

TA 0201

View more

ISA 247

View more

Acetylcysteine

View more

PRO 542

View more

FAQS